|
|
OSUCCC
 |
William E. Carson, III, M.D.
Assoc. Director for Clinical Research
Professor
College of Medicine
Surgery - Surgical Oncology
N924 Doan Hall
410 W. 10th Avenue Columbus,OH. 43210
o |
(614) 292-5819 |
f |
(614) 688-4366 |
|
Programs
|
 |
| Dr. Carson is a surgical oncologist with clinical interests in breast cancer, melanoma and general cancer surgery. His primary research focus is immunotherapy of tumors, or using drugs and other treatments to boost the human immune system's innate ability to fight tumor cells.
Carson came to Ohio State in 1997 from Roswell Park Cancer Institute in Buffalo. NY. He is a professor of surgery and of medical microbiology and immunology. In addition to his role as associate director for clinical research in the OSU Comprehensive Cancer Center (OSUCCC), he serves as co-leader of the OSUCCC's Immunology Program.
He has a number of active cancer research grants, including one in which he serves as principal investigator for a national phase II clinical trial that is testing a novel immunological approach to treating advanced malignant melanoma, the most deadly form of skin cancer.
Carson earned his bachelor's degree at the University of California, Irvine, in 1982 and his MD at the University of Southern California in 1986. |
|
Current Publications
|
|
in press: , 2009
|
|
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
|
|
Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd
|
|
|
Psychosom Med 71(7): 715-24, 2009
|
|
A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial.
|
|
Thornton LM, Andersen BL, Schuler TA, Carson WE 3rd
|
|
|
Cancer Immunol Immunother in press: , 2009
|
|
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
|
|
Lesinski GB, Benninger K, Kreiner M, Quimper M, Young G, Carson WE 3rd
|
|
|
J Clin Oncol 27(31): 5270-7, 2009
|
|
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
|
|
Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE 3rd
|
|
|
Breast Cancer Res Treat 117(1): 83-9, 2008
|
|
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
|
|
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE 3rd, Shapiro CL
|
|
|
Cancer Immunol Immunother 57(8): 1137-49, 2008
|
|
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
|
|
Kondadasula SV, Varker KA, Lesinski GB, Benson DM, Lehman A, Olencki T, Monk JP, Kendra K, Carson WE, Benson DM Jr, Carson WE 3rd
|
|
|
World J Surg Oncol 6: 79, 2008
|
|
Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy.
|
|
Liang MI, Carson WE 3rd
|
|
|
Blood 111(8): 4173-83, 2008
|
|
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
|
|
Kondadasula SV, Roda JM, Parihar R, Yu J, Lehman A, Caligiuri MA, Tridandapani S, Burry RW, Carson WE, Carson WE 3rd
|
|
|
Surg Oncol Clin N Am 16(4): 841-60, ix, 2008
|
|
Current immunotherapeutic strategies in breast cancer.
|
|
Carson WE, Liang MI
|
|
|
Cancer 113(3): 638-47, 2008
|
|
Delayed emotional recovery after taxane-based chemotherapy.
|
|
Thornton LM, Carson WE, Shapiro CL, Farrar WB, Andersen BL
|
|
|
Clin Cancer Res 14(18): 5900-6, 2008
|
|
Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.
|
|
Zimmerer JM, Lesinski GB, Ruppert AS, Radmacher MD, Noble C, Kendra K, Walker MJ, Carson WE 3rd
|
|
|
World J Surg Oncol 6: 117, 2008
|
|
Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature.
|
|
Liang MI, Ramaswamy B, Patterson CC, McKelvey MT, Gordillo G, Nuovo GJ, Carson WE 3rd
|
|
|
Cancer Res 68(20): 8351-60, 2008
|
|
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
|
|
Lesinski GB, Raig ET, Guenterberg K, Brown L, Go MR, Shah NN, Lewis A, Quimper M, Hade E, Young G, Chaudury AR, Ladner KJ, Guttridge DC, Bouchard P, Carson WE 3rd
|
|
|
Blood 111(9): 4723-30, 2008
|
|
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
|
|
Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC
|
|
|
Cancer Immunol Immunother 57(10): 1471-81, 2008
|
|
Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis.
|
|
Thornton LM, Andersen BL, Carson WE
|
|
|
Clin Cancer Res 13(17): 5010-9, 2008
|
|
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
|
|
Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X, Crespin TR, Walker MJ, Carson WE
|
|
|
Cancer 113(12): 3450-8, 2008
|
|
Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial.
|
|
Andersen BL, Yang HC, Farrar WB, Golden-Kreutz DM, Emery CF, Thornton LM, Young DC, Carson WE 3rd
|
|
|
Cancer Immunol Immunother 56(11): 1845-52, 2008
|
|
STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha.
|
|
Zimmerer JM, Lesinski GB, Radmacher MD, Ruppert A, Carson WE
|
|
|
Clin Cancer Res 13(21): 6419-28, 2008
|
|
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
|
|
Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE
|
|
|
J Interferon Cytokine Res 28(9): 553-61, 2008
|
|
VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.
|
|
Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB, Carson WE 3rd
|
|
|
